Cencora, Inc. (COR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Core Insights - The company finished a strong fiscal year 2025, with EPS and adjusted operating income both increasing by 16% [1] - The stock price has appreciated approximately 55% [1] - The company has not experienced a down year in almost 7 years, with a compounded stock price growth of 25% [1] Financial Performance - EPS and adjusted operating income growth of 16% in fiscal year 2025 [1] - Stock price increase of about 55% [1] Investor Sentiment - Investors are questioning whether they have missed the opportunity to invest in the company [1] - The discussion aims to assess the potential for continued growth and investment opportunities [1]